In addition, afatinib has been shown to inhibit the growth of gefitinib-resistant lung cancer cells harboring low levels of EGFR T790M mutation, but not those with high levels of EGFR T790M mutation [25]. The gene discussed is EGFR; the disease is lung cancer.